We are live on ! Find out more
VNDA icon

Vanda Pharmaceuticals
VNDA

99 hedge funds and large institutions have $348M invested in Vanda Pharmaceuticals in 2013 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 44 increasing their positions, 19 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

132% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 19

102% more call options, than puts

Call options by funds: $40.3M | Put options by funds: $20M

86% more capital invested

Capital invested by funds: $187M → $348M (+$160M)

86% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 14

13% more funds holding

Funds holding: 88 → 99 (+11)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
99
Holders Change
+11
Holders Change %
+12.5%
% of All Funds
3.21%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
26
Increased
44
Reduced
19
Closed
14
Calls
$40.3M
Puts
$20M
Net Calls
+$20.3M
Net Calls Change
+$8.83M

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$25.3M
2
Wells Fargo
Wells Fargo
California
+$13.4M
3
PA
Perceptive Advisors
New York
+$9.28M
4
BBA
Baker Bros. Advisors
New York
+$8.81M
5
DM
Deerfield Management
New York
+$8.76M

Top Sellers

Rank Fund Capital Flow
1
CCM
Consonance Capital Management
New York
-$9.85M
2
NI
Numeric Investors
Massachusetts
-$7.95M
3
First Eagle Investment Management
First Eagle Investment Management
New York
-$7.88M
4
BIM
Bogle Investment Management
Massachusetts
-$3.94M
5
VM
VHCP Management
New York
-$3.17M
Name Holding Trade Value Shares
Change 		Change in
Stake
Renaissance Technologies
26
Renaissance Technologies
New York
$2.81M -$1.04M -97,529 -28%
Bank of New York Mellon
27
Bank of New York Mellon
New York
$2.81M +$1.02M +95,711 +60%
BCM
28
Bridgeway Capital Management
Texas
$2.72M -$10.7K -1,000 -0.4%
QBFM
29
QS Batterymarch Financial Management
New York
$2.65M +$2.59M +242,370 New
Bank of America
30
Bank of America
North Carolina
$2.65M +$18.5K +1,731 +0.7%
HCM
31
Highbridge Capital Management
New York
$2.53M +$2.47M +230,749 New
OAM
32
Oxford Asset Management
United Kingdom
$2.42M +$2.36M +220,537 New
HCMT
33
Highland Capital Management (Texas)
Texas
$2.41M +$2.35M +219,941 New
Geode Capital Management
34
Geode Capital Management
Massachusetts
$1.98M +$78.7K +7,362 +4%
Morgan Stanley
35
Morgan Stanley
New York
$1.8M +$1.43M +133,491 +433%
NFA
36
Nationwide Fund Advisors
Ohio
$1.68M +$1.4M +131,446 +620%
Alyeska Investment Group
37
Alyeska Investment Group
Illinois
$1.65M +$1.61M +150,500 New
GS
38
Gagnon Securities
New York
$1.58M -$75.7K -7,085 -5%
RFC
39
Russell Frank Company
Washington
$1.5M +$592K +55,422 +68%
ARTA
40
A.R.T. Advisors
New York
$1.45M +$320K +29,926 +29%
NIP
41
Nicholas Investment Partners
California
$1.36M +$1.33M +124,657 New
Principal Financial Group
42
Principal Financial Group
Iowa
$1.27M +$1.08M +101,246 +687%
BIM
43
BlackRock Investment Management
Delaware
$1.02M +$181K +16,958 +22%
Ameriprise
44
Ameriprise
Minnesota
$974K +$925K +86,548 +3,939%
Prudential Financial
45
Prudential Financial
New Jersey
$947K +$228K +21,300 +33%
JGC
46
J. Goldman & Co
New York
$876K -$930K -87,000 -52%
Group One Trading
47
Group One Trading
Illinois
$842K -$786K -73,535 -49%
California Public Employees Retirement System
48
California Public Employees Retirement System
California
$823K – – –
NCCM
49
Nine Chapters Capital Management
New Jersey
$784K +$765K +71,600 New
Connor, Clark & Lunn Investment Management (CC&L)
50
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$768K +$474K +44,400 +187%
1
2
3 4 5

VNDA Hedge Fund Activity: Q3 2013 in Review

99 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q3 2013, worth a combined $348M — up 86% from $187M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new VNDA positions and 14 closed out — a net gain of 12 holders — while 44 added to existing stakes and 19 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $25.3M. The largest seller was Consonance Capital Management, cutting an estimated $9.85M.

  • 99 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q3 2013, up from 88 in Q2 2013.
  • Funds reported $348M of Vanda Pharmaceuticals stock for Q3 2013, up 86% quarter-over-quarter.
  • 26 funds opened new Vanda Pharmaceuticals positions in Q3 2013 and 14 closed out, a net change of +12 holders.
  • The largest Vanda Pharmaceuticals buyer in Q3 2013 was Fidelity Investments, an estimated $25.3M added.
  • The largest Vanda Pharmaceuticals seller in Q3 2013 was Consonance Capital Management, an estimated $9.85M sold.

Based on aggregated 13F filings for Q3 2013.